Hasan Hakan Çoban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hasan Hakan Çoban has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Süleyman Baş
Department of Internal Medicine, University of Health Sciences, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey
2 shared publications - Abdulkadir Sagdic
Department of Internal Medicine, University of Health Sciences, Eskişehir City Hospital, Eskişehir, Türkiye
1 shared publication - Akif Doğan
Department of Medical Oncology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 Istanbul, Turkey
1 shared publication - Alpaslan Tanoglu
Department of Internal Medicine, Division of Gastroenterology, Bahçeşehir University, Istanbul, Turkey
1 shared publication Alpaslan Tanoólu
Department of Internal Medicine, Bahçeşehir University, Faculty of Medicine Istanbul, Turkey
1 shared publication- Ayşe Gürbüz Yeniçeri
Department of Neurology, Sultanbeyli State Hospital, Istanbul 34935, Türkiye
1 shared publication
Latest Publications
- Open Access
Clinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study
Background and Objectives: Fingolimod, a sphingosine-1-phosphate receptor modulator, is an effective disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Although lymphopenia is a well-recognized pharmacological effect, its clinical significance remains uncertain. This study evaluated the frequency and severity of fingolimod-associated lymphopenia, longitudinal hematological changes and their relationship with clinical outcomes in a real-world MS cohort. Materials and Methods: This retrospective observational study included 143 adults with MS who initiated fingolimod treatment between May 2019 and October 2020. Demographic, clinical and laboratory data were collected at baseline and at 3- and 6-month follow-up visits. Lymphopenia was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Laboratory parameters and infection outcomes were compared according to lymphopenia severity. Logistic regression analysis was performed to identify factors associated with Grade 4 lymphopenia at 6 months. Results: At 6 months, lymphopenia was present in 124 patients (86.7%), including Grade 4 lymphopenia in 15 (10.5%). Leukocyte, neutrophil and lymphocyte counts decreased, whereas ALT, AST, GGT, NLR and SII increased significantly during treatment (all p < 0.001). Infection frequency did not differ among lymphopenia severity groups (p = 0.530). No statistically significant association was detected between Grade 3–4 lymphopenia and infection risk (OR, 1.41; 95% CI, 0.42–4.71; p = 0.545). Lower baseline lymphocyte count was independently associated with Grade 4 lymphopenia (adjusted OR 0.078, 95% CI 0.018–0.325; p < 0.001). Conclusions: Fingolimod-associated lymphopenia was common, with Grade 4 lymphopenia affecting approximately one-tenth of patients. No statistically significant association between lymphopenia severity and infection was detected; however, the small number of Grade 4 cases, low event rate and wide confidence interval limited the statistical power to exclude clinically meaningful differences. These findings should therefore be interpreted cautiously and do not establish the absence of infection risk associated with severe lymphopenia. Regular hematological monitoring and individualized clinical decision-making remain essential, particularly in patients with lower baseline lymphocyte counts.
Open AccessClinical Impact of Fingolimod-Associated Lymphopenia in Multiple Sclerosis: A Real-World Cohort Study
Background and Objectives: Fingolimod, a sphingosine-1-phosphate receptor modulator, is an effective disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Although lymphopenia is a well-recognized pharmacological effect, its clinical significance remains uncertain. This study evaluated the frequency and severity of fingolimod-associated lymphopenia, longitudinal hematological changes and their relationship with clinical outcomes in a real-world MS cohort. Materials and Methods: This retrospective observational study included 143 adults with MS who initiated fingolimod treatment between May 2019 and October 2020. Demographic, clinical and laboratory data were collected at baseline and at 3- and 6-month follow-up visits. Lymphopenia was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Laboratory parameters and infection outcomes were compared according to lymphopenia severity. Logistic regression analysis was performed to identify factors associated with Grade 4 lymphopenia at 6 months. Results: At 6 months, lymphopenia was present in 124 patients (86.7%), including Grade 4 lymphopenia in 15 (10.5%). Leukocyte, neutrophil and lymphocyte counts decreased, whereas ALT, AST, GGT, NLR and SII increased significantly during treatment (all p < 0.001). Infection frequency did not differ among lymphopenia severity groups (p = 0.530). No statistically significant association was detected between Grade 3–4 lymphopenia and infection risk (OR, 1.41; 95% CI, 0.42–4.71; p = 0.545). Lower baseline lymphocyte count was independently associated with Grade 4 lymphopenia (adjusted OR 0.078, 95% CI 0.018–0.325; p < 0.001). Conclusions: Fingolimod-associated lymphopenia was common, with Grade 4 lymphopenia affecting approximately one-tenth of patients. No statistically significant association between lymphopenia severity and infection was detected; however, the small number of Grade 4 cases, low event rate and wide confidence interval limited the statistical power to exclude clinically meaningful differences. These findings should therefore be interpreted cautiously and do not establish the absence of infection risk associated with severe lymphopenia. Regular hematological monitoring and individualized clinical decision-making remain essential, particularly in patients with lower baseline lymphocyte counts.
- 29 August 2026
- Published by Eskisehir Medical Journal, Eskisehir City Hospital in Eskisehir Medical Journal, Eskisehir City Hospital
THE RELATIONSHIP BETWEEN THE TRIGLYCERIDE-GLUCOSE INDEX AND INSULIN RESISTANCE, INFLAMMATION, IRON METABOLISM AND MICRONUTRIENT PROFILE IN INDIVIDUALS WITH OBESITY
Introduction: The aim of this study was to compare metabolic parameters, inflammatory markers, indicators of iron metabolism and micronutrient levels among groups of obese individuals categorised according to the Triglyceride-Glucose (TyG) index, and to assess the relationship between the TyG index and these parameters. Methods: The data of 110 obese individuals with a BMI ≥ 30 kg/m² who presented at Eskişehir City Hospital were retrospectively analysed. Patients were divided into two groups according to the TyG index (Group 1: TyG < 8.85, n=48; Group 2: TyG ≥ 8.85, n=62). Demographic, anthropometric and laboratory data were compared. The diagnostic performance of the TyG index in predicting insulin resistance (HOMA-IR > 2.5) was assessed using ROC analysis. Results: In Group 2, BMI (37.8±4.5 vs. 32.4±2.1 kg/m²), waist circumference (114.2±12.6 vs. 98.6±8.4 cm), HOMA-IR (5.12±1.64 vs. 2.38±0.72), CRP (5.9±1.8 vs. 2.2±0.9 mg/L), ferritin (128±34 vs. 45±12 ng/mL) and uric acid (6.4±1.2 vs. 4.8±0.8 mg/dL) were significantly higher; serum iron (58±22 vs. 85±18 μg/dL), vitamin D (14.2±6.1 vs. 22.4±8.6 ng/mL), vitamin B12 (228±74 vs. 312±88 pg/mL), folate (7.2±2.6 vs. 9.8±3.1 ng/mL) and magnesium (1.75±0.3 vs. 2.08±0.2 mg/dL) were found to be significantly low. The strongest positive correlations with TyG were observed with HOMA-IR (r=+0.67) and CRP (r=+0.61). In the ROC analysis, the AUC value of the TyG index for predicting insulin resistance was 0.85 (p<0.001), and the optimal cut-off value was determined to be 8.85 (sensitivity 76.8%, specificity 81.2%). In the gender-based subgroup analysis, elevated uric acid levels were more pronounced in men (p=0.003 for interaction). Conclusion: The TyG index is a comprehensive metabolic marker that reflects insulin resistance, alongside inflammation, iron metabolism disorders and micronutrient deficiencies, in obese individuals. The use of the TyG index in the metabolic risk assessment of obese individuals may provide clinical benefits, particularly in the early detection of functional iron deficiency and micronutrient deficiencies.
- 29 August 2026
- Published by Eskisehir Medical Journal, Eskisehir City Hospital in Eskisehir Medical Journal, Eskisehir City Hospital
THE RELATIONSHIP BETWEEN THE TRIGLYCERIDE-GLUCOSE INDEX AND INSULIN RESISTANCE, INFLAMMATION, IRON METABOLISM AND MICRONUTRIENT PROFILE IN INDIVIDUALS WITH OBESITY
Introduction: The aim of this study was to compare metabolic parameters, inflammatory markers, indicators of iron metabolism and micronutrient levels among groups of obese individuals categorised according to the Triglyceride-Glucose (TyG) index, and to assess the relationship between the TyG index and these parameters. Methods: The data of 110 obese individuals with a BMI ≥ 30 kg/m² who presented at Eskişehir City Hospital were retrospectively analysed. Patients were divided into two groups according to the TyG index (Group 1: TyG < 8.85, n=48; Group 2: TyG ≥ 8.85, n=62). Demographic, anthropometric and laboratory data were compared. The diagnostic performance of the TyG index in predicting insulin resistance (HOMA-IR > 2.5) was assessed using ROC analysis. Results: In Group 2, BMI (37.8±4.5 vs. 32.4±2.1 kg/m²), waist circumference (114.2±12.6 vs. 98.6±8.4 cm), HOMA-IR (5.12±1.64 vs. 2.38±0.72), CRP (5.9±1.8 vs. 2.2±0.9 mg/L), ferritin (128±34 vs. 45±12 ng/mL) and uric acid (6.4±1.2 vs. 4.8±0.8 mg/dL) were significantly higher; serum iron (58±22 vs. 85±18 μg/dL), vitamin D (14.2±6.1 vs. 22.4±8.6 ng/mL), vitamin B12 (228±74 vs. 312±88 pg/mL), folate (7.2±2.6 vs. 9.8±3.1 ng/mL) and magnesium (1.75±0.3 vs. 2.08±0.2 mg/dL) were found to be significantly low. The strongest positive correlations with TyG were observed with HOMA-IR (r=+0.67) and CRP (r=+0.61). In the ROC analysis, the AUC value of the TyG index for predicting insulin resistance was 0.85 (p<0.001), and the optimal cut-off value was determined to be 8.85 (sensitivity 76.8%, specificity 81.2%). In the gender-based subgroup analysis, elevated uric acid levels were more pronounced in men (p=0.003 for interaction). Conclusion: The TyG index is a comprehensive metabolic marker that reflects insulin resistance, alongside inflammation, iron metabolism disorders and micronutrient deficiencies, in obese individuals. The use of the TyG index in the metabolic risk assessment of obese individuals may provide clinical benefits, particularly in the early detection of functional iron deficiency and micronutrient deficiencies.
- Open Access
Towards Rapid Bedside Detection of Sarcopenia in Cancer Patients: The Role of Rectus Femoris Muscle Ultrasonography—A Prospective Cross-Sectional Study
Background and Objectives: Sarcopenia is a common yet underrecognized condition in cancer patients and is associated with increased treatment-related toxicity, functional decline, and poor clinical outcomes. Practical, rapid, and bedside-applicable tools are needed to detect sarcopenia early in routine oncology practice. This study aimed to evaluate the diagnostic value of rectus femoris muscle ultrasonography within an integrated clinical assessment combining handgrip strength and bioelectrical impedance analysis for the detection of sarcopenia in cancer patients. Materials and Methods: In this prospective cross-sectional study, 147 adult patients with malignancy were evaluated using a multimodal sarcopenia assessment framework. Muscle strength was assessed by handgrip dynamometry, muscle mass was estimated using bioelectrical impedance analysis (BIA)-derived appendicular skeletal muscle mass index (ASMI), and muscle morphology was evaluated using ultrasonographic measurements of the rectus femoris and biceps brachii muscles. Sarcopenia was defined and classified according to the EWGSOP2 criteria. Associations between clinical variables, BIA parameters, and ultrasonographic measurements were analyzed. Receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of muscle ultrasonography for sarcopenia detection. Results: The mean age of the study population was 60.2 ± 11.2 years, and 51% of participants were male. Confirmed sarcopenia was identified in 12.2% of patients, while 27.2% were classified as having probable sarcopenia. Sarcopenic patients were significantly older (68.5 ± 7.6 vs. 59.0 ± 11.2 years, p = 0.001) and had lower handgrip strength (15.8 ± 6.0 vs. 24.3 ± 8.4 kg, p < 0.001) and ASMI values (5.96 ± 0.64 vs. 7.23 ± 1.18 kg/m2, p < 0.001). Rectus femoris muscle thickness was significantly reduced in patients with sarcopenia (6.40 ± 1.42 vs. 8.19 ± 2.21 mm, p = 0.001). Rectus femoris muscle thickness demonstrated good diagnostic performance for sarcopenia detection (AUC = 0.752; 95% CI: 0.650–0.853; p = 0.001), with an optimal cut-off value of ≤7.59 mm (sensitivity 83.3%, specificity 61.2%). Conclusions: Rectus femoris muscle ultrasonography is a practical, rapid bedside assessment for detecting sarcopenia in cancer patients. When integrated with handgrip strength and BIA, this multimodal approach provides a feasible, radiation-free strategy for early sarcopenia screening in routine oncology practice.
Open AccessTowards Rapid Bedside Detection of Sarcopenia in Cancer Patients: The Role of Rectus Femoris Muscle Ultrasonography—A Prospective Cross-Sectional Study
Background and Objectives: Sarcopenia is a common yet underrecognized condition in cancer patients and is associated with increased treatment-related toxicity, functional decline, and poor clinical outcomes. Practical, rapid, and bedside-applicable tools are needed to detect sarcopenia early in routine oncology practice. This study aimed to evaluate the diagnostic value of rectus femoris muscle ultrasonography within an integrated clinical assessment combining handgrip strength and bioelectrical impedance analysis for the detection of sarcopenia in cancer patients. Materials and Methods: In this prospective cross-sectional study, 147 adult patients with malignancy were evaluated using a multimodal sarcopenia assessment framework. Muscle strength was assessed by handgrip dynamometry, muscle mass was estimated using bioelectrical impedance analysis (BIA)-derived appendicular skeletal muscle mass index (ASMI), and muscle morphology was evaluated using ultrasonographic measurements of the rectus femoris and biceps brachii muscles. Sarcopenia was defined and classified according to the EWGSOP2 criteria. Associations between clinical variables, BIA parameters, and ultrasonographic measurements were analyzed. Receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of muscle ultrasonography for sarcopenia detection. Results: The mean age of the study population was 60.2 ± 11.2 years, and 51% of participants were male. Confirmed sarcopenia was identified in 12.2% of patients, while 27.2% were classified as having probable sarcopenia. Sarcopenic patients were significantly older (68.5 ± 7.6 vs. 59.0 ± 11.2 years, p = 0.001) and had lower handgrip strength (15.8 ± 6.0 vs. 24.3 ± 8.4 kg, p < 0.001) and ASMI values (5.96 ± 0.64 vs. 7.23 ± 1.18 kg/m2, p < 0.001). Rectus femoris muscle thickness was significantly reduced in patients with sarcopenia (6.40 ± 1.42 vs. 8.19 ± 2.21 mm, p = 0.001). Rectus femoris muscle thickness demonstrated good diagnostic performance for sarcopenia detection (AUC = 0.752; 95% CI: 0.650–0.853; p = 0.001), with an optimal cut-off value of ≤7.59 mm (sensitivity 83.3%, specificity 61.2%). Conclusions: Rectus femoris muscle ultrasonography is a practical, rapid bedside assessment for detecting sarcopenia in cancer patients. When integrated with handgrip strength and BIA, this multimodal approach provides a feasible, radiation-free strategy for early sarcopenia screening in routine oncology practice.
- Open Access
- 9 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
A Case of Acute Pancreatitis Developing After Upper Gastrointestinal Endoscopy: A Rare Post-Procedural Complication
Acute pancreatitis is a rare but clinically significant complication of upper gastrointestinal endoscopy. Its diagnosis can be easily overlooked if abdominal symptoms are associated with the primary indication for the procedure. Although endoscopy is generally considered a reliable diagnostic tool, postprocedural pancreatitis has rarely been described in the literature, and its underlying mechanisms are not yet fully understood. Possible explanations include mechanical irritation from gastric or duodenal manipulations, increased intraluminal pressure due to air inflation, or induction of procedure-related pancreatic duct obstruction in susceptible patients. We report the case of a 57-year-old woman who underwent upper gastrointestinal endoscopy because of persistent vomiting and increasingly severe abdominal pain for a week. On presentation, she complained of a streaky, posteriorly directed upper abdominal pain and recurrent nausea and vomiting. Laboratory tests revealed elevated lipase (264.8 U/L; reference range: 13-60) and amylase (201 U/L; reference range: 28-100). Physical examination revealed marked tenderness in the upper abdomen without guarding or rebound tenderness. Imaging studies confirmed the diagnosis of acute pancreatitis. The patient was admitted to the internal medicine department and treated conservatively with analgesics, fluid therapy, and bowel rest. Her symptoms gradually improved, and she was discharged home in stable condition. This case highlights the importance of upper gastrointestinal endoscopy as a possible (albeit rare) trigger for acute pancreatitis, especially when new or worsening abdominal pain occurs shortly after the procedure. Given the limited number of published cases and the uncertainty of causal relationships, documentation of such cases is important to increase clinical awareness, guide diagnostic suspicion, and contribute to a better understanding of this rare complication.
- 9 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Open AccessA Case of Acute Pancreatitis Developing After Upper Gastrointestinal Endoscopy: A Rare Post-Procedural Complication
Acute pancreatitis is a rare but clinically significant complication of upper gastrointestinal endoscopy. Its diagnosis can be easily overlooked if abdominal symptoms are associated with the primary indication for the procedure. Although endoscopy is generally considered a reliable diagnostic tool, postprocedural pancreatitis has rarely been described in the literature, and its underlying mechanisms are not yet fully understood. Possible explanations include mechanical irritation from gastric or duodenal manipulations, increased intraluminal pressure due to air inflation, or induction of procedure-related pancreatic duct obstruction in susceptible patients. We report the case of a 57-year-old woman who underwent upper gastrointestinal endoscopy because of persistent vomiting and increasingly severe abdominal pain for a week. On presentation, she complained of a streaky, posteriorly directed upper abdominal pain and recurrent nausea and vomiting. Laboratory tests revealed elevated lipase (264.8 U/L; reference range: 13-60) and amylase (201 U/L; reference range: 28-100). Physical examination revealed marked tenderness in the upper abdomen without guarding or rebound tenderness. Imaging studies confirmed the diagnosis of acute pancreatitis. The patient was admitted to the internal medicine department and treated conservatively with analgesics, fluid therapy, and bowel rest. Her symptoms gradually improved, and she was discharged home in stable condition. This case highlights the importance of upper gastrointestinal endoscopy as a possible (albeit rare) trigger for acute pancreatitis, especially when new or worsening abdominal pain occurs shortly after the procedure. Given the limited number of published cases and the uncertainty of causal relationships, documentation of such cases is important to increase clinical awareness, guide diagnostic suspicion, and contribute to a better understanding of this rare complication.
- Open Access
- 12 June 2024
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos
- Vol. 92 (3) , 347-353
Evaluación de los parámetros inflamatorios como marcadores predictivos de malignidad en nódulos tiroideos: un estudio sobre su correlación con la clasificación de Bethesda
Objetivo: Evaluar parámetros inflamatorios como posibles marcadores de malignidad en individuos con nódulos tiroideos. Método: Se incluy...
- 12 June 2024
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos
- Vol. 92 (3) , 347-353
Open AccessEvaluación de los parámetros inflamatorios como marcadores predictivos de malignidad en nódulos tiroideos: un estudio sobre su correlación con la clasificación de Bethesda
Objetivo: Evaluar parámetros inflamatorios como posibles marcadores de malignidad en individuos con nódulos tiroideos. Método: Se incluy...
- Open Access
- 29 November 2023
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 1 (4) , 106-108
Diagnosis and treatment of hepatic encephalopathy - review
Hepatic encephalopathy is observed in patients with liver dysfunction. Therefore, chronic liver disease patients are more affected. Due to reduced liver function, neurotoxins generated by damaged intestinal flora reach the brain. Hepatic encephalopathy can be classified according to the degree of symptoms. Ammonia concentration is thought to be important in pathogenesis. Its early phases can be diagnosed with a variety of tests. and it is possible to resolve and eliminate hepatic encephalopathy with imaging and treatment.
- 29 November 2023
- Published by MediHealth Academy in Intercontinental Journal of Internal Medicine
- Vol. 1 (4) , 106-108
Open AccessDiagnosis and treatment of hepatic encephalopathy - review
Hepatic encephalopathy is observed in patients with liver dysfunction. Therefore, chronic liver disease patients are more affected. Due to reduced liver function, neurotoxins generated by damaged intestinal flora reach the brain. Hepatic encephalopathy can be classified according to the degree of symptoms. Ammonia concentration is thought to be important in pathogenesis. Its early phases can be diagnosed with a variety of tests. and it is possible to resolve and eliminate hepatic encephalopathy with imaging and treatment.